In breast cancer, CD44+CD24–, ALDH+, and CD133+ are by far commonly used molecular markers to enrich and characterize breast CSC (BCSC) (Ginestier et al., 2007; Fillmore and Kuperwasser, 2008; Wright et al., 2008; Gupta et al., 2009). Here, LDHA is linked to breast carcinoma.